Selectimmune Pharma AB (publ) reported earnings results for the fourth quarter and full year ended June 30, 2023. For the fourth quarter, the company reported net loss was SEK 2.8 million compared to SEK 2.96 million a year ago. Basic loss per share from continuing operations was SEK 0.1606 compared to SEK 0.1697 a year ago.
For the full year, net loss was SEK 8.49 million compared to SEK 14.08 million a year ago. Basic loss per share from continuing operations was SEK 0.486 compared to SEK 0.8065 a year ago.